Aquestive Therapeutics, Inc.
NASDAQ:AQST · NASDAQ Global Market
+$0.23 today
Vol 2.97M · Avg 1.51M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:AQST · Revenue to Net Income
Key Ratios
Analysis
$50.3M of revenue converted into -$68.9M of net income for the selected period. Gross margin is 62.6% and net margin is -139.2%, showing how much revenue survives after costs and taxes. EPS is $-0.61, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $44.5M -22.6% | $57.6M +13.8% | $50.6M +6.1% | $47.7M -6.2% | $50.8M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $17.2M -4.0% | $17.9M -14.2% | $20.8M +7.5% | $19.4M +29.3% | $15.0M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $27.4M -31.0% | $39.7M +33.4% | $29.8M +5.2% | $28.3M -21.1% | $35.8M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 61.5% -7.5pp | 69.0% +10.1pp | 58.8% -0.5pp | 59.3% -11.2pp | 70.5% | 9.8% | 28.9% | 38.3% |
| Research & Development | $17.2M -15.2% | $20.3M +54.8% | $13.1M -25.0% | $17.5M +2.5% | $17.0M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $79.8M +59.1% | $50.2M +58.0% | $31.8M -40.0% | $52.9M -1.1% | $53.5M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $97.0M +37.7% | $70.5M +57.1% | $44.9M -36.3% | $70.4M -0.2% | $70.5M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $559.0K -22.1% | $718.0K -46.6% | $1.3M -43.7% | $2.4M -19.5% | $3.0M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$66.1M -148.4% | -$26.6M -2351.8% | $1.2M +103.0% | -$39.6M +12.3% | -$45.1M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -148.4% -102.2pp | -46.2% -48.6pp | 2.3% +85.3pp | -83.0% +5.7pp | -88.8% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$69.7M -126.4% | -$30.8M -103.8% | -$15.1M +64.1% | -$42.1M -21.3% | -$34.7M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -156.4% -102.9pp | -53.5% -23.6pp | -29.9% +58.4pp | -88.2% -20.0pp | -68.2% | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 -100.0% | $3.4M -78.9% | $16.3M +16385.9% | $99.0K -76.6% | $423.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $17.1M +1.7% | $16.8M +125.4% | $7.5M -40.0% | $12.4M -44.6% | $22.5M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$14.1M -5.6% | -$13.4M -278.9% | $7.5M +160.6% | -$12.3M +65.6% | -$35.9M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$83.8M -89.8% | -$44.2M -479.0% | -$7.6M +86.0% | -$54.4M +22.9% | -$70.5M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -188.1% -111.4pp | -76.7% -61.6pp | -15.1% +99.0pp | -114.1% +24.7pp | -138.8% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 +100.0% | -$14.0K -105.7% | $245.0K | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$83.8M -89.8% | -$44.1M -460.8% | -$7.9M +85.5% | -$54.4M +22.9% | -$70.5M | $4.9B | $4.8B | $4.7B |
| Net Margin | -188.1% -111.4pp | -76.7% -61.1pp | -15.6% +98.6pp | -114.1% +24.7pp | -138.8% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 -49.0% | -$1 -292.3% | -$0 +88.4% | -$1 +39.5% | -$2 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 -49.0% | -$1 -292.3% | -$0 +88.4% | -$1 +39.5% | -$2 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $122.0M +40.6% | $86.7M +41.6% | $61.3M +25.7% | $48.7M +28.0% | $38.1M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $122.0M +40.6% | $86.7M +41.6% | $61.3M +25.7% | $48.7M +28.0% | $38.1M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Erasca, Inc.
NASDAQ:ERAS
$4.26B
MoonLake Immunotherapeutics
NASDAQ:MLTX
$1.42B
Esperion Therapeutics, Inc.
NASDAQ:ESPR
$656.99M
Arvinas, Inc.
NASDAQ:ARVN
$487.78M
Emergent BioSolutions Inc.
NYSE:EBS
$410.19M
Orthofix Medical Inc.
NASDAQ:OFIX
$371.68M
SNDL Inc.
NASDAQ:SNDL
$368.32M
SIGA Technologies, Inc.
NASDAQ:SIGA
$307.90M
Anavex Life Sciences Corp.
NASDAQ:AVXL
$243.26M
DarioHealth Corp.
NASDAQ:DRIO
$50.92M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does AQST generate?
Aquestive Therapeutics, Inc. (AQST) reported $44.55M of revenue in fiscal 2025.
Is AQST profitable?
Aquestive Therapeutics, Inc. (AQST) reported -$83,784,000.00 of net income, with a net margin of -188.1%.
Explore More
Continue the stock analysis
Jump to another research area for this company.